Par Drugs & Chemical opened lower at ₹114.99, compared with its previous close of ₹115.52. During today's session, the stock has traded between ₹112.21 and ₹114.99, with an average traded price of ₹112.73. It is currently showing a downward intraday trend.
return calculator
Time Period
An investment of ₹10,000 made 5 years ago in Par Drugs & Chemical is now worth
₹ 4,004.00
resulting in a loss of
₹ 5,996.00 (59.96%)
invest now
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
-2.98 (-2.58%)
Day High
₹114.99
Day Low
₹112.21
Day Open
₹114.99
Prev Close
₹115.52
Volume
4,538
Value Traded
₹0.05 Cr
1W Return
-10.53%
1M Return
-20.14%
3M Return
25.63%
6M Return
22.77%
1Y Return
8.79%
Fundamentals
Market Cap (₹ Cr.)
138
PE Ratio
9.80
PB Ratio
1.27
Dividend Yield
1.08%
ROE
11.71%
ROCE
15.09%
Book Value (₹)
91.01
Face Value (₹)
10.00
EPS (TTM)
-
Industry PE
-
Beta
-
Debt to Equity
-
Investment Returns
1 Week
-10.53%
6 Week
-
1 Month
-20.14%
3 Month
25.63%
9 Month
20.65%
Financials
Yearly
All values in ₹ crores
No data available.
Share Holding Pattern
Promoter73.41%
FII0.00%
DII0.09%
Retails & Others19.95%
Updates
22May
Par Drugs faces Rs 20.09 lakh tax demand due to filing error
Par Drugs and Chemicals Limited received an Intimation Order under Section 143(1) of the Income Tax Act, 1961, resulting in a tax demand of Rs 20,09,030. The demand includes a tax of Rs 14,79,466 and interest of Rs 5,29,563, following additions of Rs 58,78,360 to the taxable income. The company stated the demand stems from an inadvertent clerical error in the Income Tax Return and expects it to be recomputed as NIL upon rectification.
4mo ago
15May
Par Drugs & Chemicals FY26 Results: Revenue Up, Net Profit at Rs. 1,310.86 Lakhs
Par Drugs & Chemicals Limited's board approved standalone audited financial results for FY26, reporting revenue from operations of Rs. 10,365.56 lakhs and net profit of Rs. 1,310.86 lakhs. Total assets grew to Rs. 12,921.23 lakhs, while the board approved key decisions including a ₹90.00 Crore investment limit and banking facility renewal. An ongoing SEBI regulatory proceeding related to a proposed business transfer arrangement remains a key audit matter, with management's going concern assumption deemed reasonable by auditors.
